<DOC>
	<DOCNO>NCT01764464</DOCNO>
	<brief_summary>Evaluate analgesic benefit Gralise® post-laminectomy pain syndrome ( PLPS )</brief_summary>
	<brief_title>GRASSP : Gralise® Spine Surgery Pain</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Inclusion Criteria . 1 . Male female subject age 18 80 year . 2 . Primary diagnosis postlaminectomy pain syndrome ( PLPS ) , define severe pain related prior history lumbar surgery include decompressive ( e.g . laminectomy ) fusion ( e.g . posterior lumbar interbody fusion ) procedures perform L1S1 level least 6 month prior enrollment . 3 . Pain Detect score ≥12 , denote neuropathic pain probable . 4 . At least 50 % present pain intensity attribute low extremity ( Quebec Task Force Grade 3 4 ) day . 5 . All subject must decisionally capable must give consent enrol . Exclusion Criteria . 1 . Lumbar surgery &lt; 6 month prior enrollment 2 . Subjects PLPS pain free interval ( define chronic low back pain radicular symptom &lt; =3/10 ) relate indication PLPS define event new , acute subacute symptom pattern ( e.g . new disc herniation adjacent level document image ) . 3 . Subjects regularly take gabapentin pregabalin chronic pain spine surgery endorse relief ( define either minimally , much much improve 7 point likert scale ask medication ' effect ) . 4 . Having another type pain severe pain associate PLPS . 5 . An average daily pain score 10 NRS scale either screen initial washout period . 6 . Concurrent medication include antiepileptic drug ( AEDs ) ( exception : pregabalin gabapentin ) . 7 . Subjects take concomitant neuropathic pain medication ( stable dose least 4 week ) may reduce number and/or dose current pain medication : If number and/or dose exceed limit allow neuropathic pain medication ( refer Use Allowed Pain Medication ) , number and/or dose must reduce fall within acceptable limit . Concomitant neuropathic pain medication need kept stable study . 8 . Subjects previously respond treatment gabapentin dose ≥900 mg/day pregabalin dos ≥300 mg/day . 9 . Known hypersensitivity Gralise , gabapentin , ingredient . 10 . Dose limit adverse event gabapentin ; subject previously experience doselimiting adverse effect prevent titration gabapentin effective dose . 11 . History alcohol and/or drug abuse investigator 's judgment , base subject history physical examination . 12 . Subject consumes excessive amount alcohol , define great 3 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 10 ounce ] , wine [ 4 ounce ] , distilled spirit [ 1 ounce ] ) per day regular basis . 13 . Participation clinical trial investigational drug device within 30 day screen visit . 14 . Gastric reduction surgery . 15 . Acute gastrointestinal symptom diarrhea , dyspepsia , gastric duodenal ulcer . 16 . Malignancy within past 2 year basal cell carcinoma . 17 . Women pregnant breastfeeding . 18 . History seizure risk seizure due head trauma . 19 . History significant cardiovascular , respiratory , endocrine , liver kidney disease ( subject renal impairment creatine clearance &lt; 30 ml/min ) . 20 . Any significant medical condition , laboratory abnormality , psychiatric illness ( e.g . depression , mood problem , suicidal thought ) would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>post laminectomy pain syndrome , fail back surgery syndrome</keyword>
</DOC>